BioStrand is a subsidiary of ImmunoPrecise Antibodies (IPA) that leverages biotech, life science, (bio)informatics, and AI at the intersection. The company's patented HYFT technology and LENSᵃⁱ™ Integrated Intelligence Platform enable the analysis of large data sets with exceptional accuracy, providing revolutionary insights in therapeutic and diagnostic research. Established in 2019 and headquartered in Belgium, BioStrand is committed to developing an end-to-end omics drug development platform. The latest investment of €460.00K came in the form of a grant investment from Agentschap Innoveren & Ondernemen on 09 May 2022. BioStrand's unique capabilities and commitment to innovation make it a compelling player in the Biotechnology, Life Sciences, and Clean Energy industries. Learn more at biostrand.ai.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Grant | €460.00K | 1 | Agentschap Innoveren & Ondernemen | 09 May 2022 |
Seed Round | €2.00M | 1 | K & E | 25 May 2020 |
Grant | €235.00K | 1 | Agentschap Innoveren & Ondernemen | 09 May 2020 |
No recent news or press coverage available for BioStrand (a subsidiary of IPA).